Clinical holds have hampered a host of trials testing treatments for Duchenne muscular dystrophy, but one biotech is getting the go-ahead to start its study five and a half months after the initial roadblock.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,